HK1199890A1 - Neurotoxins exhibiting shortened biological activity - Google Patents

Neurotoxins exhibiting shortened biological activity

Info

Publication number
HK1199890A1
HK1199890A1 HK15100392.7A HK15100392A HK1199890A1 HK 1199890 A1 HK1199890 A1 HK 1199890A1 HK 15100392 A HK15100392 A HK 15100392A HK 1199890 A1 HK1199890 A1 HK 1199890A1
Authority
HK
Hong Kong
Prior art keywords
biological activity
neurotoxins exhibiting
shortened biological
neurotoxins
exhibiting shortened
Prior art date
Application number
HK15100392.7A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Schmidt
Jrgen Frevert
Fred Hofmann
Gerhard Groer
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48288558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1199890(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of HK1199890A1 publication Critical patent/HK1199890A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15100392.7A 2011-11-09 2015-01-14 Neurotoxins exhibiting shortened biological activity HK1199890A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161628911P 2011-11-09 2011-11-09
EP11188440 2011-11-09
US201261659137P 2012-06-13 2012-06-13
EP12171801 2012-06-13
PCT/EP2012/072158 WO2013068476A1 (fr) 2011-11-09 2012-11-08 Neurotoxines présentant une activité biologique raccourcie

Publications (1)

Publication Number Publication Date
HK1199890A1 true HK1199890A1 (en) 2015-07-24

Family

ID=48288558

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100392.7A HK1199890A1 (en) 2011-11-09 2015-01-14 Neurotoxins exhibiting shortened biological activity

Country Status (18)

Country Link
US (1) US9809809B2 (fr)
EP (1) EP2776457B1 (fr)
JP (1) JP6162135B2 (fr)
KR (1) KR20150000468A (fr)
CN (1) CN103974973A (fr)
AR (1) AR089655A1 (fr)
AU (1) AU2012334080B2 (fr)
BR (1) BR112014011137A2 (fr)
CA (1) CA2855173A1 (fr)
CL (1) CL2014001217A1 (fr)
ES (1) ES2638333T3 (fr)
HK (1) HK1199890A1 (fr)
IL (1) IL232508B (fr)
MX (1) MX351012B (fr)
RU (1) RU2646110C2 (fr)
SG (1) SG11201402131TA (fr)
TW (1) TWI583792B (fr)
WO (1) WO2013068476A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091895A1 (fr) * 2011-12-23 2013-06-27 Merz Pharma Gmbh & Co. Kgaa Nouveau procédé pour la fabrication de protéines di-chaînes pour utilisation dans les êtres humains
RU2673910C2 (ru) * 2012-11-21 2018-12-03 Ипсен Байоинновейшн Лимитед Способ производства протеолитически процессированного полипептида
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
PL2952205T3 (pl) 2014-06-06 2018-01-31 Kleiner Fisman Galit Toksyna botulinowa do zastosowania do leczenia paratonii
EP3154635A1 (fr) 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Nouvelles utilisations de neurotoxines clostridiales recombinantes présentant une durée de l'effet réduite
WO2015188943A1 (fr) 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Utilisation de neurotoxines clostridiales recombinées pour le traitement de patients souffrant de certains troubles associés aux muscles
WO2015188942A1 (fr) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Nouvelles utilisations de neurotoxines clostridiales recombinées présentant une durée d'effet réduite
US20170119863A1 (en) * 2014-06-13 2017-05-04 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3233911B1 (fr) 2014-12-19 2020-10-14 Merz Pharma GmbH & Co. KGaA Moyens et procédés pour la détermination de l'activité biologique de bont/e dans des cellules
JP6798993B2 (ja) 2014-12-23 2020-12-09 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン ボツリヌス毒素プレフィルド容器
HUE053935T2 (hu) 2015-01-09 2021-08-30 Ipsen Bioinnovation Ltd Kationos neurotoxinok
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
WO2017063743A1 (fr) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Améliorations apportées à la thérapie par ultrasons de tissu atteint de photovieillissement
MX2018008855A (es) 2016-03-02 2018-11-29 Merz Pharma Gmbh & Co Kgaa Composicion que comprende toxina botulinica.
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (fr) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Nouvelles neurotoxines clostridiales recombinantes avec augmentation de la durée d'effet
CN106432423B (zh) * 2016-09-21 2019-05-10 北京大学深圳研究生院 一种α-螺旋多肽及其用途
EP3312193A1 (fr) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Nouvelles neurotoxines botuliques recombinantes à augmentation de la durée d'effet
CN110691579A (zh) 2017-03-22 2020-01-14 邦蒂公司 用于治疗的肉毒杆菌神经毒素
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
EP3649143B1 (fr) * 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Nouvelles neurotoxines botuliques recombinantes présentant une durée d'effet accrue
WO2019133179A2 (fr) * 2017-12-01 2019-07-04 Massachusetts Institute Of Technology Sélection par affinité en phase solution d'inhibiteurs à partir de bibliothèques combinatoires de peptides
WO2019158745A1 (fr) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Neurotoxine botulique reposant sur un acide nucléique, pour application thérapeutique
CN112135840B (zh) * 2018-03-13 2024-01-23 斯米维特公司 与破伤风神经毒素结合的单域抗体
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
CN109666683B (zh) * 2019-02-27 2021-10-29 昆明理工大学 乙酰辅酶A乙酰转移酶基因RKAcaT2及其应用
CN110721314B (zh) * 2019-10-11 2022-11-29 江苏恒泰生物科技有限公司 一种抗肿瘤纳米药物及其制备方法
SE2050326A1 (en) * 2020-03-25 2021-06-29 Jonathan Davies Engineered botulinum neurotoxin serotype E
CN111763663B (zh) * 2020-07-09 2022-04-15 昆明理工大学 一种天麻葡糖基转移酶基因及应用
CN112410321B (zh) * 2020-11-26 2022-01-28 昆明理工大学 一种β-葡萄糖苷酶Ttbgl3及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69738754D1 (de) * 1996-07-05 2008-07-17 Cancer Rec Tech Ltd Hemmer der interaktion zwischen p53 und mdm2
GB9708089D0 (en) 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to stabilising substances in cells
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6678651B2 (en) * 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
KR100852821B1 (ko) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
WO2008106507A2 (fr) * 2007-02-27 2008-09-04 University Of South Florida Peptide inhibiteur de mdm2/mdmx
CA2680741A1 (fr) * 2007-03-22 2009-01-15 The Regents Of The University Of California Anticorps monoclonaux therapeutiques qui neutralisent les neurotoxines botuliniques
US7732579B2 (en) * 2007-06-13 2010-06-08 The United States Of America As Represented By The Secretary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type A
EP2178905B1 (fr) * 2007-07-26 2013-11-06 Allergan, Inc. Procédés d'activation de toxines clostridiales
FR2924721B1 (fr) * 2007-12-10 2010-02-26 Cytomics Systems Procede de criblage d'agents modulant l'activite de l'ubiquitine ligase mdm2 et moyens destines a la mise en oeuvre dudit procede
US20100278826A1 (en) * 2008-06-10 2010-11-04 Shoemaker Charles B Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins
US8343743B2 (en) * 2008-06-10 2013-01-01 Synaptic Research, Llc Designer ubiquitin ligases having a non-cleavable SNAP25 domain and E3-ligase domain
BRPI1014253A2 (pt) * 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento

Also Published As

Publication number Publication date
RU2646110C2 (ru) 2018-03-01
AR089655A1 (es) 2014-09-10
CL2014001217A1 (es) 2014-10-10
AU2012334080B2 (en) 2016-12-15
EP2776457B1 (fr) 2017-08-02
WO2013068476A1 (fr) 2013-05-16
SG11201402131TA (en) 2014-08-28
ES2638333T3 (es) 2017-10-19
TW201326390A (zh) 2013-07-01
US20140308267A1 (en) 2014-10-16
MX2014005544A (es) 2014-05-30
CA2855173A1 (fr) 2013-05-16
US9809809B2 (en) 2017-11-07
CN103974973A (zh) 2014-08-06
IL232508A0 (en) 2014-06-30
JP6162135B2 (ja) 2017-07-12
TWI583792B (zh) 2017-05-21
JP2014533945A (ja) 2014-12-18
IL232508B (en) 2018-06-28
BR112014011137A2 (pt) 2018-06-12
KR20150000468A (ko) 2015-01-02
RU2014123060A (ru) 2015-12-20
AU2012334080A1 (en) 2014-05-15
MX351012B (es) 2017-09-28
EP2776457A1 (fr) 2014-09-17

Similar Documents

Publication Publication Date Title
HK1199890A1 (en) Neurotoxins exhibiting shortened biological activity
HK1171246A1 (zh) 顯示出縮短的生物學活性的神經毒素
DK3421595T3 (da) Alfa-amylasevarianter
BR112013012217A2 (pt) incubadora
HK1207881A1 (en) Improved enzyme variants
GB201100282D0 (en) Biological methods
GB201112231D0 (en) Micro-organism
GB201202599D0 (en) Beleuchtungseinrichtung fur fahrzeuge
SG11201403280PA (en) Bioreactor
GB201109756D0 (en) Bacteria
SG11201404524WA (en) Methods for identifying agents with desired biological activity
EP2712404A4 (fr) Système à base d'aquifère à usage multiple
GB201118026D0 (en) Biosensor
GB201106615D0 (en) Assay
EP2939081A4 (fr) Alignement d'activité périodique
GB2505638B (en) Continuous culture
EP2486851C0 (fr) Affichage pour des valeurs biologiques
GB201102659D0 (en) Assay
GB201117453D0 (en) Improved sperm function/activity
GB201009658D0 (en) Incubator
ZA201108590B (en) Neurotoxins exhibiting shortened biological activity
GB201100792D0 (en) Incubators
GB201119467D0 (en) Biological methods
GB201202413D0 (en) Activity support
GB201114673D0 (en) Biological products